Effect of Ayurvedic Medicines (Modified Nisha Amalaki Vati and Dashmooladi Kwatha) along with Dhanyamla Dhara and Standard Treatment in the Management of Diabetic Polyneuropathy

Efficasy of Nisha Amalaki Vati(modified) and Dashmooladi Kwatha along with Dhanyamla Dhara as add-on to conventional medicine in the management of Madhumehajanya Upadrava(Diabetic polyneuropathy)- A Randomised Standard control Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/111568

Enrollment

Registered

2026-06-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G63- Polyneuropathy in diseases classified elsewhere

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of both the genders having the age between 30 to 70 years. 2.Patient fulfilling the diagnostic criteria. 3.Patients on oral Hypoglycemic agents and/or insulin. (FBS less than 250mg/dl) 4.Patients who are symptomatic even after taking the standard control of diabetic polyneuropathy.(more than 3 months) 5.Mild to moderate Neuropathy patients having Toronto score between 6 to 11 will be included.

Exclusion criteria

Exclusion criteria: 1.Patient aged below 30 years and above 70 years 2.Patients having other known causes of peripheral neuropathies such as vitamin B12 deficiency, addiction or history of alcohol consumption. 3.Patients with known autoimmune diseases (SLE, Rheumatoid arthritis), infections (HIV, hepatitis B and C), inflammatory (Chronic Inflammatory Demyelinating Polyneuropathy), hypothyroidism and injury or pressure on the nerve. 4.Patients with K/C/O Cerebral vascular disease, leprosy, HIV-AIDS, STDs and other immune-compromised conditions. 5.Patients with other severe complications of Diabetes mellitus like ketoacidosis, DKD [GFR less than 15 mL/min] 6.Patients with active /healing / non healing diabetic foot ulcer. 7.Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
1.Improvement in neuropathic symptoms 2.Changes in Vibration perception threshold score. 3.Changes in glycemic panel.(FBS,PPBS,HbA1C) Timepoint: 3 months	—

Secondary

Measure	Time frame
1.Improvement in the quality of life of patient having diabetic polyneuropathyTimepoint: 90 days	—

Countries

India

Contacts

Public ContactDr Megha Pandya

ITRA Jamnagar

meghapandya@itra.edu.in9409714186

Outcome results